Why the study?
Do Direct Oral Anticoagulants (DOACs) reduce the risk of dementia compared to warfarin in an Asian population with atrial fibrillation?
Do Direct Oral Anticoagulants (DOACs) reduce the risk of dementia compared to warfarin in an Asian population with atrial fibrillation?
Answers are grounded in this paper and cite their sources.
In an Asian population with atrial fibrillation, DOACs have a comparable overall risk of dementia to warfarin, though edoxaban may offer a lower risk.
In this large Asian population with atrial fibrillation, DOAC showed a comparable risk of dementia with warfarin overall. DOACs appeared more beneficial than warfarin, in those aged 65 to 74 years or with a history of stroke. For specific DOACs, only edoxaban was associated with a lower risk of dementia than warfarin.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: